Fig. 5
From: Advances in immunotherapy for triple-negative breast cancer
The diagram CAR-T cell, NK cell and CIK cell separately or with others anticancer approaches to treat TNBC. GD2-CAR-T cells, MUC28z CAR-T cells and a fibrin gel containing CAR-T cells demonstrate a significantly higher inhibitory effect on tumor cell growth in TNBC. NK cells derived from cancer patients exhibit heightened cytotoxicity against TNBC cell lines and xenograft tumor models. The combination therapy of RTand NK cells, Avelumab, Selenocystine/TGF-β Inhibitor, Ruthenium complexes, Aptamer-engineered approach enhance the cytotoxic effects mediated by NK cells. EGFR-CAR NK cells exhibited cytotoxicity and anti-tumor properties against TNBC cell lines. The combination administration of CIK cells and cetuximab or CIK cells and FAK inhibitor has been shown to significantly impede the growth, metastasis, and dissemination of TNBC